NASDAQ:DVAX - Dynavax Technologies Stock Price, Forecast & News

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies Co. (NASDAQ:DVAX) posted its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.10. The biopharmaceutical company had revenue of $10.58 million for the quarter, compared to analysts' expectations of $10.31 million. Dynavax Technologies had a negative return on equity of 399.60% and a negative net margin of 519.95%. The company's revenue was up 624.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.65) earnings per share. View Dynavax Technologies' Earnings History.

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Dynavax Technologies.

Dynavax Technologies will be holding an earnings conference call on Wednesday, March 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

5 brokerages have issued 1-year target prices for Dynavax Technologies' shares. Their forecasts range from $13.00 to $20.00. On average, they anticipate Dynavax Technologies' stock price to reach $15.33 in the next year. This suggests a possible upside of 278.1% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

Press coverage about DVAX stock has been trending negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dynavax Technologies earned a news sentiment score of -2.8 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Dynavax Technologies.

Some companies that are related to Dynavax Technologies include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Array Biopharma (ARRY), United Continental (UAL), Kite Pharma (KITE), Cara Therapeutics (CARA) and Exelixis (EXEL).

Dynavax Technologies' stock is owned by many different of institutional and retail investors. Top institutional investors include Chicago Capital LLC (4.77%), Senvest Management LLC (4.76%), Bain Capital Public Equity Management II LLC (4.24%), State Street Corp (4.11%), UBS Asset Management Americas Inc. (2.08%) and Blair William & Co. IL (2.01%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies.

DVAX stock was sold by a variety of institutional investors in the last quarter, including Senvest Management LLC, Point72 Asset Management L.P., Chicago Capital LLC, FMR LLC, DekaBank Deutsche Girozentrale, Rhenman & Partners Asset Management AB, Bank of America Corp DE and Gables Capital Management Inc.. Company insiders that have sold Dynavax Technologies company stock in the last year include David Louis Johnson, Michael S Ostrach and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.

DVAX stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Bain Capital Public Equity Management II LLC, Oxford Asset Management LLP, Rafferty Asset Management LLC, California Public Employees Retirement System, Alpine Global Management LLC, Blair William & Co. IL and Bank of New York Mellon Corp. View Insider Buying and Selling for Dynavax Technologies.

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DVAX stock can currently be purchased for approximately $4.06.

Dynavax Technologies has a market capitalization of $340.07 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe.View Additional Information About Dynavax Technologies.

The official website for Dynavax Technologies is http://www.dynavax.com/.

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]